Current Duke Appointments & Affiliations
Assistant Professor of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2024 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Proper Phenotyping of Pancreatic Cancer in Database Research.
Journal article JAMA Oncol · July 23, 2026 Full text Link to item CiteClinical and genomic predictors of sipuleucel-T outcomes in men with metastatic androgen pathway modulator resistant prostate cancer.
Journal article Res Sq · July 1, 2026 BACKGROUND: Survival outcomes following sipuleucel-T in men with metastatic androgen pathway modulator resistant prostate cancer (mAPMR) are variable. Genomic alterations influencing immune response and tumor proliferation may explain outcome heterogeneity ... Full text Link to item CitePhase 2 multicenter trial of chemoimmunotherapy for patients with neuroendocrine or aggressive variant metastatic prostate cancer (CHAMP).
Conference Journal of Clinical Oncology · June 1, 2026 5016Background: Platinum-doublet chemotherapy is effective in pts with neuroendocrine ... Full text CiteRecent Grants
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer (KLK2-PASenger, 78278343PCR3003)
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2026 - 2030A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2024 - 2029TulmiSTAR-02: A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in c
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2025 - 2029View All Grants
Education
Icahn School of Medicine at Mount Sinai ·
2017
M.D.